drugset / Trial / NCT04932915

Safety and Efficacy of Intranasal Administration of Niclosamide (UNI91103) in Adults With Asymptomatic or Mild COVID-19

NCT04932915

Phase 2 Terminated 4 enrolled UNION therapeutics
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety and efficacy of UNI91103 intranasal spray for treatment of coronavirus disease 2019 (COVID-19) in asymptomatic or mildly symptomatic adults.

Timeline

Start
2021-09-03
Primary completion
2022-01-10
Completion
2022-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Niclosamide Unknown 1 % Intranasal

Indications